Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells

Through comprehensive comparison study, we found that ibrutinib, a clinically approved covalent BTK kinase inhibitor, was highly active against EGFR (L858R, del19) mutant driven NSCLC cells, but moderately active to the T790M ‘gatekeeper’ mutant cells and not active to wild-type EGFR NSCLC cells. Ib...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Oncotarget
Κύριοι συγγραφείς: Wu, Hong, Wang, Aoli, Zhang, Wei, Wang, Beilei, Chen, Cheng, Wang, Wenchao, Hu, Chen, Ye, Zi, Zhao, Zheng, Wang, Li, Li, Xixiang, Yu, Kailin, Liu, Juan, Wu, Jiaxin, Yan, Xiao-E, Zhao, Peng, Wang, Jinhua, Wang, Chu, Weisberg, Ellen L., Gray, Nathanael S., Yun, Cai-Hong, Liu, Jing, Chen, Liang, Liu, Qingsong
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Impact Journals LLC 2015
Θέματα:
Research Paper
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741607/
https://ncbi.nlm.nih.gov/pubmed/26375053
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια